Elamipretide for Adult Patients with Primary Mitochondrial Disease

Elamipretide for Adult Patients with Primary Mitochondrial Disease

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

The goal of this study is to evaluate the safety and efficacy of an investigational drug called "Elamipretide" in adult patients with mitochondrial disease. "Investigational" means the study drug has not been approved by the U.S. Food and Drug Administration (FDA) and its use in this study is experimental.

The study will last for approximately 13 months and will include at least 7 outpatient visits at CHOP, where participants will be provided the study drug (randomized to active drug or placebo) and monitored for safety.  The clinical trial also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures.  For more information: https://clinicaltrials.gov/ct2/show/NCT05162768

You will also receive travel support and reimbursement for related expenses.

Eligibility and criteria
IRB Number:
22-019628
Eligible age range:
18 years - 70 years
Clinical trial phase:
Phase III
Official title:
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.